Nuovi Approcci Terapeutici Nel Trattamento Del Carcinoma Del Colon-Retto in Stadio Avanzato

Bowen Benson A. III : Therapy for advanced colorectal cancer. Semin. Oncol., 25(Suppl. 11): 2–11, 1998.

The advanced colorectal cancer meta-analysis project: Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. J. Clin. Oncol., 10: 896–903, 1992.

The advanced colorectal cancer meta-analysis project: Metaanalysis of randomized trials testing the biochemical modulation of fluorouracil by methotrexate in metastatic colorectal cancer. J. Clin. Oncol., 12: 960–969, 1994.

The meta-analysis group in cancer: Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J. Clin. Oncol., 16: 301–308, 1998.

Rothenberg M.L. : Efficacy and toxicity of irinotecan in patients with colorectal cancer. Semin. Oncol., 25(Suppl. 11): 39–46, 1998.

Rougier P. , Van Cutsem E. , Bajetta E. , Niederle N. , Possinger K. , Labianca R. , Navarro M. , Morant R. , Bleigerg H. , Wils J. , Awad L. , Herait P. , Jacques C. : Randomized trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet, 352: 1407–1412, 1998.

Cunningham D. , Pyrhönen S. , James R.D. , Punt C.J.A. , Hickish T.F. , Heikkila R. , Johanesen T.B. , Starkhammar H. , Topham C.A. , Awad L. , Jacques C. , Herait P. : Randomized trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet, 352: 1413–1418, 1998.

Rixe O. , Ortuzar W. , Alvarez M. , Parker R. , Reed E. , Paull K. , Fojo T. : Oxaliplatin, tetraplatin, cisplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen Panel. Biochem. Pharmacol., 52: 1855–1865, 1996.

Raymond E. , Chaney S.G. , Taamma A. , Cvitkovic E. : Oxaliplatin: a review of preclinical and clinical studies. Ann. Oncol., 9: 1053–1071, 1998.

Becouarn Y. , Ychou M. , Ducreux M. , Borel C. , Bertheault-Cvitkovic F. , Seitz J.F. , Nasca S. , Nguyen T.D. , Paillot B. , Raoul J.L. , Duffour J. , Fandi A. , Dupont-Andre G. , Rougier P. : Phase II trial of oxaliplatin as first-line chemotherapy in metastatic colorectal cancer patients. Digestive Group of French Federation of Cancer Centers. J. Clin. Oncol., 16: 2739–2744, 1999.

Diaz Rubio E. , Sastre J. , Zaniboni A. , Labianca R. , Cortés-Funes H. , de Braud F. , Boni C. , Benavides M. , Dallavalle G. , Homerin M. : Oxaliplatin as single agent in previously untreated colorectal carcinoma patients: a phase II multicentric study. Ann. Oncol., 9: 105–108, 1998.

Machover D. , Diaz-Rubio E. , de Gramont A. , Schilf A. , Gastiaburu J.J. , Brienza S. , Itzhaki M. , Metzger G. , N'Daw D. , Vignoud J. , Abad A. , François E. , Gamelin E. , Marty M. , Sastre J. , Seitz J.F. , Ychou M. : Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines. Ann. Oncol., 7: 95–98, 1996.

Raymond E. , Buquet-Fagot C. , Dielloul S. , Mester J. , Cvitkovic E. , Allain P. , Louvet C. , Gespach C. : Antitumor activity of oxaliplatin in combination with 5-fluorouracil and the thymidylate synthase inhibitor AG337 in human colon, breast and ovarian cancers. Anti-Cancer Drugs, 8: 876–885, 1997.

de Gramont A. , Figier A. , Seymour M. : A randomized trial of leucovorin (LV) and 5-fluorouracil (5FU) with or without oxaliplatin in advanced colorectal cancer (CRC). J. Clin. Oncol., in press.

Giacchetti S. , Zidani R. , Perpoint B. , Faggiuolo R. , Focan C. , Letourneau Y. , Chollet P. , Llory J.F. , Coudert B. , Bertheault-Cvitkovic F. , Adam R. , Le Bail N. , Misset J.L. , Bayssas M. , Lèvi F. : Phase III trial of 5-fluorouracil (5-FU), folinic acid (FA), with or without oxaliplatin in previously untreated patients (pts) with metastatic colorectal cancer (MCC). Proc. Am. Soc. Clin. Oncol., 16: 885, 1997.

Sun Y. , Guan Z.Z. , Jin M.L. , Shi T.Z. , Li W.L. , Zhou L.Z. , Sui G.J. , Li L.Q. , Xu L.G. , Zhang J.Q. , Song S.P. , Li R. , Xu D.F. , Li Y. , Huang F.L. , Brienza S. , Ju L.Y. : A multicenter randomized phase II trial of oxaliplatin alone and in combination in patients with advanced colorectal cancer in China. Proc. Am. Soc. Clin. Oncol., 18: 979, 1999.

Zori Comba A. , Blajiman C. , Richardet E. , Vilanova M. , Coppola F. , Van Kooten M. , Rodger J. , Giglio R. , Balbiani L. , Perazzo F. , Montiel M. , Chacon M. , Pujol E. , Mickiewicz E. , Cazap A. , Recondo G. , Kotliar M. , Nesis P. , Reale M. , Lastiri F. , Schmilovich A. : Bimonthly oxaliplatin (L-OHP) with (A) or without (B) fluorouracil (FU) and leucovorin (FA): proven evidence of synergism in a phase II randomized trial. Proc. Am. Soc. Clin. Oncol., 18: 953, 1999.

Gerard B. , Bleiberg H. , Van-Daele D. , Gil T. , Hendslisz A. , Di Leo A. , Fernez B. , Brienza S. : Oxaliplatin combined to 5-fluorouracil and folinic acid: an effective therapy in patients with advanced colorectal cancer. Anticancer Drugs, 9: 301–305, 1998.

Andre T. , Louvet C. , Raymond E. , Turnigand C. , de Gramont A. : Bimonthly high-dose leucovorin, 5-fluorouracil infusion and oxaliplatin (FOLFOX3) for metastatic colorectal cancer resistant to the same leucovorin and 5-fluorouracil regimen. Ann. Oncol., 9: 1251–1253, 1998.

de Braud F. , Munzone E. , Nole F. , De-Pas T. , Biffi R. , Brienza S. , Aapro M.S. : Synergistic activity of oxaliplatin and 5-fluorouracil in patients with metastatic colorectal cancer with progressive disease while on or after 5-fluorouracil. Am. J. Clin. Oncol., 21: 279–283, 1998.

de Gramont A. , Vignoud J. , Tournigand C. , Louvet C. , Andre T. , Varette C. , Raymond E. , Moreau S. , Le Bail N. , Krulik M. : Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer. Eur. J. Cancer, 33: 214–219, 1997.

Van Cutsem E. , Szanto J. , Roth A. , Humblet Y. , Köhne J. , Wils J. , Lorenz M. , Borner P. , Schöffski P. , Tabah-Fisch I. : Evaluation of the addition of oxaliplatin to the same Mayo or German 5FU regimen in advanced refractory colorectal cancer (ARCRC). Proc. Am. Soc. Clin. Oncol., 18: 900, 1999.

Bleiberg H. , Brienza S. , Gerard B. , Di Leo A. , Hendlisz A. , Van Daele D. , Cornez N. , Geurs F. , Duriau D. , Bertaux B. : Oxaliplatin combined with a high dose, 24-hour continuous 5FU infusion and folinic acid based regimen in patients with advanced colorectal cancer (CRC). Proc. Am. Soc. Clin. Oncol., 18: 925, 1999.

Bensmaine M.A. , Marty A. , de Gramont A. , Misset J.L. , Cuvier C. , Chollet P. , Conroy T. , Chauvenet L. , Ducreux M. , Laplaige P. , Untereiner M. , Jacob J.H. , Gamelin E. , Sutherland W. , Cvitkovic E. : Extended access French program (EAFP) of oxaliplatin ± 5FU in 5FU-refractory advanced colorectal cancer (RACRC) patients. Proc. Am. Soc. Clin. Oncol., 18: 973, 1999.

Janinis J. , Fountzilas G. , Skarlos D.V. , Efstathiou E. , Aravantinos G. , Papakostas P. : Second line combination chemotherapy with weekly oxaliplatin (1-OHP) and high dose 5-fluorouracil (5-FU) with leucovorin (LCV) in metastatic colorectal carcinoma (MCC). A Hellenic Cooperative Oncology Group Study. Proc. Am. Soc. Clin. Oncol., 18: 978, 1999.

Guerin-Meyer V. , Delva R. , Lortholary A. , Maillart P. , Boisdron-Celle M. , Merkanter B. , Brienza S. , Chouaki N. , Larra F. , Gamelin E. : Combination of oxaliplatin (OXA)/5-FU/FA in 5-FU refractory advanced colorectal cancer (RACRC) patients (pts) treated with 5-FU/FA weekly pk guided regimen. Proc. Am. Soc. Clin. Oncol., 18: 1001, 1999.

Maindrault-Goebel F. , de Gramont A. , Louvet C. , Andre T. , Carola E. , Gilles-Amar V. , Lotz J.P. , Izrael V. , Krulik M. : High-dose oxaliplatin with the simplified 48h bimonthly leucovorin (LV) and 5-fluorouracil (5FU) regimen in pretreated metastatic colorectal cancer (FOLFOX). Proc. Am. Soc. Clin. Oncol., 18: 1017, 1999.

Kemeny N. : Chemotherapy for colorectal carcinoma: one small step forward, one step backward. J. Clin. Oncol., 13: 1287–1290, 1995.

Bradpiece H.A. , Benjamin I.S. , Halevy A. , Blumgart H. : Major hepatic resection for colorectal liver metastases. Br. J. Surg., 74: 324–326, 1987.

Steele G. Jr. , Bleday R. , Mayer R.J. , Lindblad A. , Petrelli N. , Weaver D. : A prospective evaluation of hepatic resection for colorectal carcinoma metastases to the liver: gastrointestinal tumor study group protocol 6584. J. Clin. Oncol., 9: 1105–1112, 1991.

Giacchetti S. , Itzhaki M. , Gruia G. , Adam R. , Zidani R. , Kunstlinger F. , Brienza S. , Alafaci E. , Bertheault-Cvitkovic F. , Jasmin C. , Reynes M. , Bismuth H. , Misset J.L. , Levi F. : Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery. Ann. Oncol., 10: 663–669, 1999.

Lévi F. , Zidani R. , Brienza S. , Dogliotti L. , Perpoint B. , Rotarski M. , Letourneau Y. , Llory J.F. , Chollet P. , Le Rol A. , Focan C. : A multicenter evaluation of intensified, ambulatory, chronomodulated chemotherapy with oxaliplatin, 5-fluorouracil and leucovorin as initial treatment of patients with metastatic colorectal carcinoma. International Organisation for Cancer Chronotherapy. Cancer, 85: 2532–2540, 1999.